Perfromance Wealth Partners LLC Acquires Shares of 2,000 BioNTech SE (NASDAQ:BNTX)

Perfromance Wealth Partners LLC acquired a new stake in BioNTech SE (NASDAQ:BNTX) in the third quarter, HoldingsChannel reports. The institutional investor acquired 2,000 shares of the company’s stock, valued at approximately $238,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BNTX. Virtu Financial LLC purchased a new position in BioNTech in the 4th quarter valued at about $274,000. Goldman Sachs Group Inc. boosted its position in BioNTech by 17.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 182,878 shares of the company’s stock valued at $19,301,000 after buying an additional 26,777 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in BioNTech by 207.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,583 shares of the company’s stock valued at $273,000 after buying an additional 1,743 shares during the last quarter. GAMMA Investing LLC boosted its position in BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after buying an additional 150 shares during the last quarter. Finally, Green Alpha Advisors LLC boosted its position in BioNTech by 12.9% in the 1st quarter. Green Alpha Advisors LLC now owns 5,819 shares of the company’s stock valued at $537,000 after buying an additional 666 shares during the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on BNTX shares. Bank of America increased their price target on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. HSBC increased their price target on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. Morgan Stanley raised shares of BioNTech from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $93.00 to $145.00 in a research report on Tuesday, September 24th. TD Cowen reduced their price target on shares of BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. Finally, UBS Group increased their price target on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 18th. Five equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.92.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $120.52 on Friday. The firm’s 50 day moving average is $100.90 and its two-hundred day moving average is $93.36. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The firm has a market capitalization of $28.66 billion, a P/E ratio of -53.33 and a beta of 0.24. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The firm had revenue of $128.70 million during the quarter, compared to analyst estimates of $134.98 million. During the same quarter in the previous year, the business posted ($0.86) EPS. BioNTech’s revenue for the quarter was down 23.3% compared to the same quarter last year. Analysts anticipate that BioNTech SE will post -3.04 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.